PerpEquities

Abivax S.A. (ABVX) cash flow statement

NASDAQ · Healthcare · Biotechnology · 80 employees · CEO Marc de Garidel

Price
$86.59 -2.77%
Market cap
$7.58B
Enterprise value
€6.41B
Last report
Q2 '26 filed 2026-09-21
Next report
2026-12-21

In Q2 '26 Abivax S.A. (ABVX) generated -€52M of operating cash flow, invested €112K in capital expenditure and kept -€52.1M of free cash flow. Over the last four quarters free cash flow was –.

Cash flow

Cash flowTrendQ4 '20Q2 '21Q4 '21Q2 '22Q4 '22Q2 '23Q4 '23Q2 '24Q4 '24Q2 '25Q4 '25Q2 '26
Operating
Net income-€22.1M-€16.5M-€24.8M-€21.2M-€40.3M-€52M-€95.8M-€38.8M-€52.4M-€48.4M-€222M-€117M
Depreciation & amortization€33K€32K€124K€39K€32K€329K€378K€365K€273K€251K€367K€374K
Stock-based compensation€0€0€0€0€262K€56K€0€5.67M€4.69M€6.33M-€11M€16.8M
Deferred income tax€0€0€0€0€0€0€0€0€0€0€0-€6.08M
Change in working capital€2.73M-€5.9M€4.49M-€4.19M€4.51M-€6.42M€12M-€17M€9.01M€6.45M€1.22M€1.24M
Other non-cash items-€2.05M-€1.3M-€1.43M€1.94M€5.23M€30.4M€12.2M-€715K€5.12M€2.04M€160M€53.1M
Operating cash flow-€21.5M-€23.8M-€21.9M-€25.8M-€39.8M-€27.6M-€71.2M-€50.4M-€33.3M-€33.3M-€71.3M-€52M
Investing
Capital expenditure-€552K-€129K-€1.51M-€80K-€3.89M-€149K-€117K-€224K-€44K-€19K-€73.4K-€112K
Acquisitions€186K€222K€90K€0€14K€0€0€0€18K€22K€0€6K
Purchases of investments€0€0€0-€3.72M€3.57M€0-€9.35M€0-€6K€0-€13.6M€0
Sales / maturities of investments€0€0€0€25K€365K€57K€684K€0€0€0€480K€0
Other investing-€702K-€124K-€2K€0-€21K-€1.62M€1K€11.8M€1.11M€184K€16.5M€1.57M
Investing cash flow-€1.07M-€31K-€1.43M-€3.77M€44K-€1.71M-€8.78M€11.6M€1.08M€187K€3.28M€1.47M
Financing
Net debt issued / repaid€0€0€0-€5.54M€0€0€0€20.3M-€6.12M-€6.91M-€43.3M-€104K
Share buybacks€0€0€0-€13K€0€0€0€0€0€0€0€0
Other financing (incl. tax on vested shares)€39.8M-€1.16M€79.7M-€175K€40.2M€118M€223M-€1.23M-€1.71M-€1.85M€57.9M-€39.2M
Financing cash flow€39.8M-€1.16M€79.7M-€6.43M€40.2M€118M€223M€19.1M-€7.84M-€8.77M€603M-€39.3M
Summary
FX effect on cash€0€0€0€0-€1K€6K-€2.54M€451K-€612K-€1.17M-€7.16M-€4.48M
Net change in cash€17.2M-€25M€56.4M-€34.1M€379K€87.4M€138M-€19.3M-€40.6M-€42.6M€529M-€89.4M
Free cash flow (OCF - capex)-€22M-€23.9M-€23.4M-€25.8M-€43.7M-€29M-€71.3M-€50.6M-€33.3M-€33.4M-€71.3M-€52.1M
Interest paid€0€0€0€0€0€0€0€0€0€0-€3.87M€0

Standardised from the company's filings; outflows and costs keep the sign the provider reports. Hover a period for its end date. Amounts in EUR.

Operating cash flow, capex, free cash flow

quarterly

Uses of cash vs operating cash flow

fiscal years

Share count and EPS

quarterly, diluted

The other statements

Sources

Statements, segment revenue, metrics and estimates are standardised from the company's filings.

Data as of 2026-11-02 · Amounts in EUR as reported; price and market cap in USD.